Osler, Hoskin & Harcourt acted as Canadian counsel to Milestone Pharmaceuticals Inc. in the offering, Cooleyacted as US counsel to the company. Wilmer Cutler Pickering Hale...
Milestone Pharmaceuticals’ $34.5 Million Common Shares Offering
Linden Capital Partners’ Acquisition of Alcresta Therapeutics
Kirkland & Ellis represented Linden Capital Partners, Wilmer Cutler Pickering Hale and Dorr represented Alcresta Therapeutics and Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital. Linden...
Kymera Therapeutics’ $316.2 Million Common Stock Offering
Goodwin Procter advised Kymera Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Kymera Therapeutics, Inc. (Nasdaq: KYMR) (“Kymera”) announced its...
Celldex Therapeutics’ $230.5 Million Common Stock Offering
Lowenstein Sandler advised Celldex Therapeutics, Inc. on the offering, and Wilmer Cutler Pickering Hale and Dorr advised the underwriters. Celldex Therapeutics, Inc. (Nasdaq: CLDX) (“Celldex”) announced the...
Omeat’s $40 Million Funding Round
Wilmer Cutler Pickering Hale and Dorr represented Omeat Inc. in the transaction. Omeat Inc. announced it has secured $40 million in funding as it emerges from stealth...
Gemini Therapeutics’ Combination with Disc Medicine
Wilmer Cutler Pickering Hale and Dorr advised Gemini, while Goodwin Procter advised Disc Medicine. Fried, Frank, Harris, Shriver & Jacobson acted as counsel to SVB Securities...
Voyager Therapeutics’ License Option Agreement with Novartis
WilmerHale advised Voyager Therapeutics on the deal. Voyager Therapeutics, a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, announced it entered into...
CinCor Pharma’s $193.6 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Viridian Therapeutics’ $97.7 Million Shares Offering
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering...
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Tecan’s $1 Billion Acquisition of Paramit Corporation
Wilmer Cutler Pickering Hale, Dorr LLP and Skrine and Bär & Karrer advised The Tecan Group on the deal, while Schiff Hardin LLP represented Paramit Corporation....